Zoetis (ZTS) Scheduled to Post Earnings on Monday

Zoetis (NYSE:ZTS) is scheduled to issue its quarterly earnings data before the market opens on Monday, November 4th. Analysts expect the company to announce earnings of $1.46 per share for the quarter. Zoetis has set its FY24 guidance at $5.78-5.88 EPS and its FY 2024 guidance at 5.780-5.880 EPS.Individual interested in participating in the company’s earnings conference call can do so using this link.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.49 by $0.07. The company had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The firm’s revenue was up 8.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.41 earnings per share. On average, analysts expect Zoetis to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Zoetis Stock Down 0.8 %

Shares of NYSE:ZTS opened at $180.01 on Monday. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The firm has a 50 day simple moving average of $189.10 and a 200-day simple moving average of $177.89. The company has a market capitalization of $82.14 billion, a PE ratio of 34.68, a P/E/G ratio of 2.94 and a beta of 0.89. Zoetis has a twelve month low of $144.80 and a twelve month high of $201.92.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a $0.432 dividend. The ex-dividend date is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.96%. Zoetis’s dividend payout ratio (DPR) is presently 33.14%.

Analysts Set New Price Targets

ZTS has been the topic of a number of research analyst reports. Stifel Nicolaus lifted their target price on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. BTIG Research boosted their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Piper Sandler upped their price target on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.